MedTrace Logo

Efficacy Study of CLR3001 in Depression

NCT01158547 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 86

Last updated 2015-02-04

No results posted yet for this study

Summary

The purpose of this study is to assess the ability of CLR3001 to reverse depressive symptoms relatively quickly in adult patients with major depressive disorder (MDD).

Conditions

Sponsors & Collaborators

  • University Health Network, Toronto

    collaborator OTHER

  • Clera Inc.

    lead OTHER

Principal Investigators

  • Sidney Kennedy, M.D. · University Health Network, Toronto

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01158547 on ClinicalTrials.gov